“We are pleased to welcome Mr. Mueller to our board of directors. Brian’s global experience in financial operations and extensive experience with strategic transactions will most certainly add value to Anthera as we continue to advance our late-stage clinical trials,” said Dr. Chris Henney, chairman of Anthera Pharmaceuticals.
Mueller, who earned his bachelor’s degree in Accountancy from NIU, has been with BioMarin since 2002 after a combination of seven years in public accounting in Arthur Andersen, LLP and KPMG, LLP.
“We look forward to leveraging Brian’s accomplishments at BioMarin and his leadership in guiding us through our next stage of growth,” Henney added.